Thanks for the response. While the share price and the market cap are especially low, mainly due to the financial situation of the company, which is admittedly "difficult", the MOA of the products are sound and the clinical data is sound and positive when you omit certain unexpected/unfortunate circumstances.
E.g. The HCC trial showed good results and would have met it's endpoint if not all of the most severe (shorter life span) patient-subtype had been almost mathematically impossibly all been randomised to the treatment group and none to placebo.
The prior psoriasis data which was just shy of it's primary endpoint and with better long-term results that Celgene's Otezla was based on general population of psoriasis patients, where as in the ongoing Phase III they are specifically recruiting those patients with high target receptor which is shown to have much greater drug efficacy. Again the MOA is roughly similar to leading biologics in Psoriasis but oral and without the side-effects.
RA data we'll just have to see results from Phase III.
NASH: Based on the HCC trial true positive outcome combined with the Pre-clin model strongly significant results on the same markets as the NASH trial, then the NASH data coming out later this year should be quite positive. Also when comparing Genfit's Elafibranor MOA to Namodenoson they both act on similar outcomes.
Watching this for now. Will see their upcoming NASH data as well as how they manage their finances towards Phase III completions with probably another raise I guess, but as far as the science, data and Phase III trial designs go, looks promising.
Just a thought.
